NZ602350A - Kinase inhibitors and method of treating cancer with same - Google Patents

Kinase inhibitors and method of treating cancer with same

Info

Publication number
NZ602350A
NZ602350A NZ602350A NZ60235011A NZ602350A NZ 602350 A NZ602350 A NZ 602350A NZ 602350 A NZ602350 A NZ 602350A NZ 60235011 A NZ60235011 A NZ 60235011A NZ 602350 A NZ602350 A NZ 602350A
Authority
NZ
New Zealand
Prior art keywords
cancer
kinase inhibitors
same
treating cancer
spiro
Prior art date
Application number
NZ602350A
Other languages
English (en)
Inventor
Peter Brent Sampson
Yong Liu
Sze-Wan Li
Bryan T Forrest
Heinz W Pauls
Louise G Edwards
Miklos Feher
Narendra Kumar B Patel
Radoslaw Laufer
Guohua Pan
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of NZ602350A publication Critical patent/NZ602350A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
NZ602350A 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same NZ602350A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32133210P 2010-04-06 2010-04-06
US32132910P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
PCT/CA2011/000386 WO2011123946A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Publications (1)

Publication Number Publication Date
NZ602350A true NZ602350A (en) 2014-05-30

Family

ID=44761967

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602350A NZ602350A (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Country Status (25)

Country Link
US (9) US8263596B2 (enExample)
EP (2) EP2556071B1 (enExample)
JP (1) JP5442906B2 (enExample)
KR (1) KR101782668B1 (enExample)
CN (1) CN102892766B (enExample)
AU (1) AU2011238384B2 (enExample)
BR (1) BR112012025496B1 (enExample)
CY (1) CY1118610T1 (enExample)
DK (1) DK2556071T3 (enExample)
EA (1) EA023173B1 (enExample)
ES (2) ES2603613T3 (enExample)
HR (1) HRP20161498T1 (enExample)
HU (1) HUE030651T2 (enExample)
IL (1) IL221556A (enExample)
LT (1) LT2556071T (enExample)
ME (1) ME02545B (enExample)
MX (1) MX2012011516A (enExample)
NZ (1) NZ602350A (enExample)
PL (1) PL2556071T3 (enExample)
PT (1) PT2556071T (enExample)
SG (1) SG183875A1 (enExample)
SI (1) SI2556071T1 (enExample)
SM (1) SMT201600430B (enExample)
TW (1) TWI516262B (enExample)
WO (2) WO2011123947A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008340991B2 (en) 2007-12-21 2012-02-23 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) * 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
DK2878594T3 (en) * 2012-07-27 2019-02-04 Sato Pharma DIFLUOROMETHYLENE COMPOUND
CN105764899B (zh) * 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
MX357763B (es) 2013-10-18 2018-07-23 Univ Health Network Tratamiento para cancer pancreatico.
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
WO2018145525A1 (zh) 2017-02-08 2018-08-16 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
CN108947961B (zh) * 2017-05-18 2021-06-04 四川大学 吲唑类衍生物及其制备方法和用途
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
MA55767A (fr) * 2019-04-24 2022-03-02 Univ Health Network Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate
CN115397429A (zh) * 2019-12-06 2022-11-25 大学健康网络 急性髓性白血病或骨髓增生异常综合征治疗
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112250614B (zh) * 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
WO2022240876A1 (en) 2021-05-11 2022-11-17 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2024006379A1 (en) * 2022-06-30 2024-01-04 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1247803A3 (en) 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
JP2002540096A (ja) 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
AU2003286604A1 (en) * 2002-10-21 2004-05-13 Irm Llc Oxindoles with anti-hiv activity
WO2005058309A1 (en) 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
WO2008152014A2 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
MX2010003249A (es) 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
CA2706075A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
AU2008340991B2 (en) * 2007-12-21 2012-02-23 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
JP5593234B2 (ja) * 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
WO2010008731A1 (en) 2008-06-16 2010-01-21 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010115279A1 (en) * 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
CA2850394C (en) 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
CN105764899B (zh) 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
MX357763B (es) 2013-10-18 2018-07-23 Univ Health Network Tratamiento para cancer pancreatico.

Also Published As

Publication number Publication date
US8921545B2 (en) 2014-12-30
EA023173B1 (ru) 2016-04-29
CN102892766B (zh) 2015-05-20
TWI516262B (zh) 2016-01-11
SI2556071T1 (sl) 2016-12-30
BR112012025496B1 (pt) 2021-02-23
SG183875A1 (en) 2012-10-30
EP2556071A4 (en) 2013-09-04
CN102892766A (zh) 2013-01-23
US8481533B2 (en) 2013-07-09
US9796703B2 (en) 2017-10-24
PT2556071T (pt) 2016-11-22
US8263596B2 (en) 2012-09-11
EP2556070A4 (en) 2013-10-23
JP5442906B2 (ja) 2014-03-19
CY1118610T1 (el) 2017-07-12
LT2556071T (lt) 2017-01-25
HUE030651T2 (en) 2017-05-29
ES2639757T3 (es) 2017-10-30
KR101782668B1 (ko) 2017-09-27
PL2556071T3 (pl) 2017-02-28
US20130096301A1 (en) 2013-04-18
DK2556071T3 (en) 2016-12-12
JP2013523784A (ja) 2013-06-17
US20180105511A1 (en) 2018-04-19
AU2011238384B2 (en) 2015-02-19
IL221556A (en) 2015-04-30
AU2011238384A1 (en) 2012-09-27
MX2012011516A (es) 2013-03-08
KR20130108065A (ko) 2013-10-02
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
US20110263598A1 (en) 2011-10-27
US20150133677A1 (en) 2015-05-14
BR112012025496A2 (pt) 2020-08-18
US9139563B2 (en) 2015-09-22
EP2556070A1 (en) 2013-02-13
ME02545B (me) 2017-02-20
ES2603613T3 (es) 2017-02-28
SMT201600430B (it) 2017-01-10
US10077255B2 (en) 2018-09-18
US9907800B2 (en) 2018-03-06
HRP20161498T1 (hr) 2016-12-16
WO2011123946A8 (en) 2011-12-08
US10358436B2 (en) 2019-07-23
US9579327B2 (en) 2017-02-28
EP2556070B1 (en) 2017-06-07
US20140045838A1 (en) 2014-02-13
EA201270752A1 (ru) 2013-04-30
US20160045511A1 (en) 2016-02-18
US20120264800A1 (en) 2012-10-18
US20170226088A1 (en) 2017-08-10
WO2011123946A1 (en) 2011-10-13
TW201134471A (en) 2011-10-16
EP2556071A1 (en) 2013-02-13
WO2011123947A8 (en) 2011-12-22
EP2556071B1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
NZ602350A (en) Kinase inhibitors and method of treating cancer with same
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
IL261964A (en) Transformed gasoline compounds
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
MX2018003861A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
UA100400C2 (uk) Похідні спіроциклічних амідів
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
WO2014091298A3 (en) Nitrogen containing morphinan derivatives and the use thereof
GEP201606555B (en) Compounds and compositions for modulating egfr activity
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
IN2012DN01983A (enExample)
EP4257591A3 (en) Inhibitors of lysine specific demethylase-1
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EA201401062A1 (ru) Бициклические пиразиноновые производные
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
MX357502B (es) Derivados de pirrolotriazinona.
WO2014105958A3 (en) Fused pyrimidine compounds and use thereof
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
GB201209587D0 (en) Therapeutic compounds
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317